ArticleBrain & spine2025
Profiles of survival prediction in glioblastoma.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioblastomas are aggressive brain tumors. While the extent of resection of contrast-enhancing-tumor on MRI correlates with improved survival, the prognostic value of other tumor compartments remains unclear. Research question: We aimed to find neuroimaging predictive profiles related to postoperative outcomes.Clinical and volumetric data were collected from 214 glioblastoma patients. Material and methods: Quantitative volumetric measurements were performed on pre-/postoperative MRI using a 3D-semi-automatic-segmentation-software. Volumetric parameters were correlated with clinical outcomes using non-parametric tests and principal component analyses. Results: Mean overall survival was 16.51 months, mean progression-free survival 12.53 months. Mean contrast-enhancing tumor was 16.60 cm Discussion and conclusion: Our regression trees show that clinical factors and volumetric compartments play a significant role in predicting survival in glioblastoma patients. While linear correlations of volumetric parameters and survival may not clearly be identified, a multifactorial individualized approach to surgical management has the potential to benefit patients and facilitate individual treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.